Aktive Positionen von Gordon Brooks
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARMO BIOSCIENCES INC | Direktor/Vorstandsmitglied | 21.06.2018 | - |
| DERMIRA, INC. | Direktor/Vorstandsmitglied | 20.02.2020 | - |
| SIGILON THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 11.08.2023 | - |
Karriereverlauf von Gordon Brooks
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Director/Board Member | 3 |
Sektoral
| Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
- Börse
- Insiders
- Gordon Brooks
- Erfahrung